A new article in Calcalist (Hebrew) telling the Imagene story and details our Oncology Intelligence: Vision Foundation Model Engine designed to decode cancer from biopsy images. This State-of-the-Art Foundation Model facilitates the development of unlimited downstream research applications beyond biomarker profiling, including predicting treatment responses, disease prognosis, and discovering novel biomarkers through the identification of pathological features. #foundationmodel #oncologyintelligence #OCI Oracle Cloud https://lnkd.in/e_QsFVxg
Imagene
Medical and Diagnostic Laboratories
Philadelphia , PA 7,008 followers
Immediate Oncology Intelligence
About us
Imagene was founded with a clear mission to leverage AI to profile, within minutes, a broad range of cancer biomarkers from a digitized biopsy image alone. By doing so we can overcome economical, logistical, and technological barriers to reach the full potential of precision medicine for all cancer patients. Imagene's technology classifies patterns that cannot be seen by the human eye, evolving genomics, proteomics, and spatial insights resulting in a fast and accurate molecular profiling. Our technology also enables better stratification of patients for clinical trials and the discovery of novel targets for new drugs. We are a diverse startup with bright, passionate and most of all fun team. Our success derives from our cutting-edge technology and talented multidisciplinary team of data scientists, biologists, software engineers, and medical experts. Imagene collaborates with top-tier medical centers and pharmaceutical companies worldwide. The fight against cancer is profound and the world needs talented and innovative people - If you are looking for a meaningful and challenging job – Join Us!
- Website
-
https://imagene-ai.com
External link for Imagene
- Industry
- Medical and Diagnostic Laboratories
- Company size
- 11-50 employees
- Headquarters
- Philadelphia , PA
- Type
- Privately Held
- Founded
- 2020
Locations
-
Primary
Get directions
2400 Market Street
No. 200
Philadelphia , PA 19103, US
-
Get directions
Yitzhak Sadeh 17
Tel Aviv, IL
Employees at Imagene
-
Avital Rabani
B2B Marketer and Strategist, VP of Marketing @Imagene
-
Addie Dvir
Personalized medicine leader, Next generation AI image-based molecular analysis
-
Will Brown, MBA
Business & Commercial Operations Leader in Life Science, Pharma & Healthcare Technology. Adjunct Professor of Business & Entrepreneurship.
-
Yevhenia Dudnyk
Product Manager at Imagene AI
Updates
-
Thank you Rachel Dangur for acknowledging our talk. Indeed Imagene's Oncology Intelligence engine powered by Oracle holds the power to transform cancer diagnosis, research and care #precisiononcology #OCI #oncologyintelligence
I really enjoyed enriching my knowledge today at the future of AI Conference led by Ben Pelled, a leader in the FinTech and AI Conferences. We had the opportunity to get insights from AI leaders on optimizing innovation both internally and externally within organizations. I feel compelled to keep up with the rapid pace of that sector development, as I believe it's my duty, as well as that of every business development, sales, and innovation leader, to explore opportunities for enhancing organizational efficiency to achieve more success with fewer resourceses. Additionally, identifying avenues for implentation of innovative tools to meet business goals and increase revenue through additional tools is crucial. As part of my journey in learning about integrating AI in healthcare, it was fascinating to discover today the collaboration between Imagene and Oracle Cloud. As Imagene's VP of marketing director, Avital Rabani presented today, their mutual development of an "oncologic brain" that can not only diagnose mutations by learning millions of Biopsies exams, but also answer complex questions like treatment responsiveness, patient profile matching for clinical trials, and more. This promises will be creating accessibility, saving resources and time for numerous researchers and physicians. I am truly curious to see how I, along with other industry leaders in healthcare, can realize these opportunities and turn them from vision into implementation for companies growth, and advancing our healthcare industry through technological breakthroughs. #AIinnovation #healthcareinnovation #healhtech #AI #startupnation
-
-
Imagene reposted this
It was great to be on stage with Omri Stone, Oracle at "The Future of AI" conference, discussing the importance of AI in cancer diagnosis and research. Imagene #precisiononcology #oncologyintelligence #OCI
-
-
The recent article in The Lancet, "Lung cancer treatment: 20 years of progress," underscores the remarkable advancements in lung cancer therapies over the past two decades, bringing new hope with targeted treatments and precision medicine. Despite these breakthroughs, a significant number of patients worldwide are still not benefiting from these innovations due to limited access to diagnostic testing. At Imagene AI, we recognize the crucial need for molecular testing and biomarker profiling to ensure patients receive the best possible care. Our rapid AI-based NSCLC biomarker test, LungOI, is designed to bridge this gap by providing quick and accurate results. Additionally, our Oncology Intelligence: Vision Foundation Model Engine is specifically designed to decode cancer from biopsy images, facilitating the development of unlimited downstream research applications, including predicting treatment responses and disease prognosis as well as discovering novel biomarkers through the identification of pathological features. It's essential to address the disparity in access to these life-saving technologies. We are committed to advancing genomics for all, ensuring that more patients can benefit from the latest advancements in cancer treatment. #precsionmedicine #biomarkers #cancerresearch https://lnkd.in/e_jT-CsE
Lung cancer treatment: 20 years of progress
thelancet.com
-
Congratulations to Prof. Christian Rolfo, MD, PhD, MBA,Dr.h.c. on his appointment as Director of the Division of Medical Oncology at The Ohio State University Comprehensive Cancer Center (OSUCCC – James). We are proud to have such an accomplished leader and expert on Imagene AI's scientific advisory board. Your contributions to oncology and precision medicine continue to inspire us all! https://lnkd.in/eTVsvDse #Oncology #Leadership #CancerResearch
Ohio State appoints Christian Rolfo to lead Division of Medical Oncology
cancer.osu.edu
-
Great to have you onboard Jessica Riley Indeed amazing 3 days, and many more to come!
Sat on the plane, reflecting on the past three days at the ASCO conference and it has been nothing short of energizing, filled with back-to-back meetings and invaluable interactions. Here are some of my highlights: ✔️Receiving invaluable feedback from our early access users about the product market fit of ImageneOI, our Biomarker Profiling Platform ✔️All the discussions with our strategic and commercial partners who are instrumental in helping us achieve our goals with data access, clinical trial, and clinical pipeline deployments. ✔️Welcoming new customers of our first-in-class LungOI LDT, enabling rapid turnaround of patient diagnostic results to get them on the right drug faster. ✔️Connecting with pharma companies eager to leverage our solutions to enhance biomarker strategies, speed up patient enrollment, and ensure pull-through for their on-market drugs. ✔️It was also fantastic to finally meet in person and spend quality time with some of my new team at Imagene AI (Daniel, Addie and Dean), as well as catching up with the usual suspects and good friends at all the receptions. By the end of it all I, like many who attended, am thoroughly exhausted but not at all complaining. What remains at the forefront of my mind is how exhausted our patients are from their cancer journeys and as an experienced survivor, knowing first-hand the pitfalls in our systems that desperately need fixing, it truly motivates me to keep striving for better solutions. Until next year, Chi-Town! #ASCO2024 #ImmediateOncologyIntelligence #FoundationOI #ImageneOI #LungOI
-
-
June 2nd is #NationalCancerSurvivorsDay! We honor cancer survivors and those still fighting this complex disease. We also recognize the dedication of pathologists and oncologists guiding patients hand-in-hand through this difficult journey. Imagene AI stays committed to advancing cancer care. #NCSD2024 #CancerSurvivorsDay
-
-
Imagene reposted this
We're excited to share the culmination of key milestones of our flag ship product LungOI - CLIA certification, LDT product launch, and Medicare code and rate. This marks a pivotal step in making rapid biomarker profiling more accessible, enhancing patient care by triaging patient samples to a primary diagnostic assay. The LungOI AI-based NSCLC Biomarker Profiling test was developed using our core technology, a state-of-the-art Oncology Intelligence Foundation Model specifically designed to address oncology diagnostic and research challenges. Our executive team will be showcasing our full product line at the upcoming #ASCO2024, May 31 - June 4, Booth #10064. Schedule a meeting in advance: https://lnkd.in/eFhX-Ydd https://lnkd.in/e-z6MGgv #NSCLC #precisiononcology #biomarkers #immediateoncologyintelligence #LungOI #CLIA #FoundationModel
Imagene Advances LungOI Commercialization With New Payment Code and Pricing, Complementing Its Prior CLIA Certified US Lab
newswire.com
-
We're excited to share the culmination of key milestones of our flag ship product LungOI - CLIA certification, LDT product launch, and Medicare code and rate. This marks a pivotal step in making rapid biomarker profiling more accessible, enhancing patient care by triaging patient samples to a primary diagnostic assay. The LungOI AI-based NSCLC Biomarker Profiling test was developed using our core technology, a state-of-the-art Oncology Intelligence Foundation Model specifically designed to address oncology diagnostic and research challenges. Our executive team will be showcasing our full product line at the upcoming #ASCO2024, May 31 - June 4, Booth #10064. Schedule a meeting in advance: https://lnkd.in/eFhX-Ydd https://lnkd.in/e-z6MGgv #NSCLC #precisiononcology #biomarkers #immediateoncologyintelligence #LungOI #CLIA #FoundationModel
Imagene Advances LungOI Commercialization With New Payment Code and Pricing, Complementing Its Prior CLIA Certified US Lab
newswire.com
-
How often do you get an NGS report and just can't find what you need to treat your patient? Some of our esteemed scientific advisors have collaborated to establish new reporting standards for NGS results in NSCLC. In the era of precision oncology, the increasing variety of targeted therapies, NGS platforms, and bioinformatics algorithms makes interpreting these reports increasingly complex. Their new recommendations for report annotations and workflow are now connecting the dots for clinicians, enabling them to leverage the power of precision oncology in real world practice. Congratulations to Christian Rolfo, MD, PhD, MBA,Dr.h.c., Natasha Leighl, Nir Peled, Dov Hershkovitz, Maximilian Hochmair, and their collaborators on this significant achievement! Their insights highlight the importance of early communication between pathologists and oncologists, which enhances actionability and reduces turnaround time. Adopting these recommendations will improve the clarity and the access toward advanced, precise, and personalized cancer treatments! https://lnkd.in/eJrjRbkE #CancerResearch #Oncology #MolecularDiagnostics #NextGenerationSequencing #PrecisionMedicine #NSCLC #HealthcareInnovation
Recommendations for reporting tissue and circulating tumour (ct)DNA next-generation sequencing results in non-small cell lung cancer - British Journal of Cancer
nature.com